Patent ID: 11970541
Assignee: BEIJING MABWORKS BIOTECH CO. LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for treating an autoimmune disease, comprising administering an effective amount of humanized anti-CD20 antibodies to a subject in need thereof, wherein said humanized anti-CD20 antibodies comprising:
a light chain comprising the amino acid sequence of SEQ ID NO: 1,
a heavy chain comprising the amino acid sequence of SEQ ID NO: 2, and
N-glycans that are attached to the Fc region of the antibody, wherein the N-glycans are not bisected by N-acetylglucosamine, and the N-Glycans comprise G0-GN, G0, G0F, Man5, G1, G1′ and G2.